50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Hims & Hers health CFO sells $488,530 in stock

Published 23/12/2024, 22:44
Hims & Hers health CFO sells $488,530 in stock
HIMS
-

SAN FRANCISCO—Okupe Oluyemi, the Chief Financial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold shares of the company’s Class A Common Stock valued at approximately $488,530. The transactions, executed on December 20, 2024, were part of a pre-established trading plan under Rule 10b5-1.

The sales were conducted as part of a structured trading plan adopted on May 31, 2024, allowing executives to sell a predetermined number of shares at specific times. These plans are often used to avoid potential accusations of insider trading. Trading at a P/E ratio of 57.6x, HIMS is one of 1,400+ US stocks covered by detailed Pro Research Reports, offering investors comprehensive analysis and actionable insights. Trading at a P/E ratio of 57.6x, HIMS is one of 1,400+ US stocks covered by detailed Pro Research Reports, offering investors comprehensive analysis and actionable insights.

The sales were conducted as part of a structured trading plan adopted on May 31, 2024, allowing executives to sell a predetermined number of shares at specific times. These plans are often used to avoid potential accusations of insider trading.

In other recent news, Hims & Hers Health has experienced significant developments. The U.S. Food and Drug Administration (FDA) recently announced the resolution of the tirzepatide injection shortage, a decision that could impact the market dynamics for obesity drugs. Hims & Hers Health, which had been offering compounded versions of obesity drugs, experienced a sharp decline in shares following this announcement.

In a contrasting development, Morgan Stanley (NYSE:MS) initiated coverage on Hims & Hers Health with an Overweight rating, citing a strong investment opportunity. The firm highlighted the company’s impressive revenue compound annual growth rate projection of 30% from 2024 to 2026. The company’s third-quarter sales also exceeded market expectations, with a year-over-year increase of 77%, surpassing $400 million.

Meanwhile, Hims & Hers Health announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. This collaboration involves integrating with LillyDirect, a self-pay pharmacy channel, further enhancing the company’s service offerings. However, a similar partnership between digital health company Ro and Eli Lilly resulted in a slight drop in Hims & Hers Health shares.

Finally, in a report from Hunterbrook Media, it was suggested that the company could benefit from potential FDA leadership ties. The report indicates that the company’s future could be positively impacted by President-elect Donald Trump’s nominee for the FDA commissioner, Dr. Martin Makary, currently an executive at Sesame, a telehealth company that also sells compounded GLP-1 drugs online.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.